ONdrugDelivery - Page 29 of 57 - ONdrugDelivery - drug delivery industry specialised b2b information

MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission

MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission

With evidence indicating that the established antiparasitic ivermectin can kill coronavirus in a laboratory setting in under 48 hours, MedinCell has published data showing that long-acting formulations of ivermectin can be designed with varying doses and durations with its BEPO® technology and is investigating whether a long-acting product could be effective in breaking the chain of viral transmission.

INHALER FOR DIRECT PULMONARY DELIVERY OF ANTI-IL-6 MAB IN COVID-19

INHALER FOR DIRECT PULMONARY DELIVERY OF ANTI-IL-6 MAB IN COVID-19

Tiziana Life Sciences has developed a handheld inhaler that will allow the rapid delivery of TZLS-501, its drug to treat inflammation of the lung in COVID-19. The company believes TZLS-501 (anti-IL6R) combined with this newly introduced inhalation technology may rapidly inhibit inflammation in lungs and in combination with intravenous administration may deplete circulating levels of IL-6 and potentially halt progression of COVID-19-mediated lung damage and death.

THERAVANCE ADVANCES TO CLINICAL TRIALS WITH TD-0903 IN COVID-19 ACUTE LUNG INJURY

THERAVANCE ADVANCES TO CLINICAL TRIALS WITH TD-0903 IN COVID-19 ACUTE LUNG INJURY

Theravance Biopharma is advancing TD-0903, a lung-selective nebulised Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with acute lung injury (ALI) in patients hospitalised COVID-19 patients. The goal is the prevention of disease progression to ARDS.

BIOHAVEN GIVEN FDA GO-AHEAD TO BEGIN PHASE II TRIAL OF INTRANASAL VAZEGEPANT IN COVID-19 LUNG INFLAMMATION

BIOHAVEN GIVEN FDA GO-AHEAD TO BEGIN PHASE II TRIAL OF INTRANASAL VAZEGEPANT IN COVID-19 LUNG INFLAMMATION

Biohaven is to initiate a Phase II trial within weeks of intranasal vazegepant, its third-generation, high-affinity, selective small molecule CGRP receptor antagonist, in pulmonary complications of COVID-19 disease. The clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some cases can be fatal in COVID-19.

CALL FOR HELP IN THE FIGHT AGAINST COVID-19! BUSINESSES UNITE TO SUPPLY 15,000 FACE VISORS A DAY TO NHS

CALL FOR HELP IN THE FIGHT AGAINST COVID-19! BUSINESSES UNITE TO SUPPLY 15,000 FACE VISORS A DAY TO NHS

A growing group of businesses is urgently calling for more companies to join its initiative to put in place an end-to-end supply chain for desperately needed protective face visors for NHS and other workers in the fight against COVID-19. The group aims to achieve volumes of approx. 15,000 units/day.

DEVICE DESIGN CONSULTANCIES JOIN FORCES, STEP-UP TO THE COVID-19 VENTILATOR CHALLENGE

DEVICE DESIGN CONSULTANCIES JOIN FORCES, STEP-UP TO THE COVID-19 VENTILATOR CHALLENGE

Leading device design consultancies Cambridge Consultants, PA Consulting, Sagentia, Team Consulting and TTP , with industrial assistance from MetLase, have joined forces to answer the UK government's call for the rapid development and manufacture of vital ventilators for patients suffering with severe symptoms of COVID-19.

Development of IMV’s DPX-COVID-19 Vaccine Progresses Apace

Development of IMV’s DPX-COVID-19 Vaccine Progresses Apace

Canadian biotech company IMV has made impressively rapid, solid progress on the development of a vaccine candidate against the novel coronavirus, using its lipid-based vaccine delivery platform, DPX. New developments in just two weeks include, include: initiation of peptide candidate manufacturing, cGMP scale-up plans, preclinical models/assays; and Phase I clinical trial design completed, with discussions with Health Canada already underway also.

Aquavit Developing Microchannel Drug Delivery Device / Novel Compositions for Vaccine Against COVID-19

Aquavit Developing Microchannel Drug Delivery Device / Novel Compositions for Vaccine Against COVID-19

Aquavit Pharmaceuticals is applying its AQUAGOLD® microchannel drug delivery device in the development of a self-administered dermal vaccine against COVID-19 caused by the SARS-CoV-2 coronavirus.

Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months

Stabilitech to have oral coronavirus vaccine ready for preclinical evaluation in 3 months

UK biopharma company Stabilitech is developing OraPro-COVID-19, applying its OraPro technology with the aim of developing a viral vector with six weeks, and having a capsule ready for animal testing within 12 weeks.

TEQ supporting ‘Essential Business’ activity with European sourcing of medical packaging

TEQ supporting ‘Essential Business’ activity with European sourcing of medical packaging

TEQ is delivering a range of medical packaging solutions for customers working to address critical health needs related to covid-19.

Vero Biotech gets okay for expanded access to its Genosyl DS iNO system to treat COVID-19 patients

Vero Biotech gets okay for expanded access to its Genosyl DS iNO system to treat COVID-19 patients

The US FDA has granted “Expanded Access Emergency Use” to Vero Biotech immediately to use its proprietary inhaled nitric oxide (iNO) delivery system, GENOSYL DS, in the treatment of cardiopulmonary symptoms associated with COVID-19. The agency recently approved GENOSYL (NO) gas, for inhalation for the treatment of persistent pulmonary hypertension of the newborn.

N4 demonstrating utility of Nuvec<sup>®</sup> vaccine delivery system in COVID-19 vaccines using COVID-19 DNA plasmid

N4 demonstrating utility of Nuvec^® vaccine delivery system in COVID-19 vaccines using COVID-19 DNA plasmid

N4 Pharma has initiated a proof of concept project using a Covid-19 DNA plasmid to demonstrate the utility of its Nuvec® silica nanoparticle vaccine delivery system for potential collaboration partners developing Covid-19 DNA or RNA vaccines.

Springboard offers medical device expertise to tackle COVID-19

Springboard offers medical device expertise to tackle COVID-19

Springboard is now offering: design reviews / risk assessments of COVID-19 related medical devices at no charge; answering ad hoc requests for advice on devices relevant to COVID-19 at no charge; device development expertise, including a willingness to tackle short term projects on a not-for profit basis; submission of services to the UK Gov call for businesses to help make NHS ventilators.

UPDATE AND NEWS FROM ONDRUGDELIVERY’S PUBLISHER IN RESPONSE TO COVID-19

UPDATE AND NEWS FROM ONDRUGDELIVERY’S PUBLISHER IN RESPONSE TO COVID-19

The world, and our industry with it, has entered an unfamiliar and difficult period. I would like to take this opportunity to update you on how ONdrugDelivery can and will continue to provide its services uninterrupted, and tell you about some specific initiatives we're launching to help our readers, authors and clients across the global industry.

COVID-19, what’s left to be said and done?…well, everything!

COVID-19, what’s left to be said and done?…well, everything!

John Cahill, Director, Senior Consultant, Quality & Compliance, PharmaLex Ireland, provides an update on the status of several COVID-19 vaccine and therapeutic development programmes, emphasising the considerable efforts being made by industry, regulatory agencies and others, to accelerate development in what is normally, due to the need for stringent regulation, a notoriously slow-moving sector.

Windtree Therapeutics to study its KL4 surfactant for COVID-19 pulmonary effects

Windtree Therapeutics to study its KL4 surfactant for COVID-19 pulmonary effects

Windtree Therapeutics plans a pilot study to assess its KL4 surfactant's ability to impact key respiratory parameters in ventilated COVID-19 patients. The COVID-19 virus infects the specific cells that make pulmonary surfactant and is believed to result in inadequate levels of functional surfactant.

eTheRNA launches international consortium, starts development of cross-strain protective CoV-2 mRNA vaccine

eTheRNA launches international consortium, starts development of cross-strain protective CoV-2 mRNA vaccine

An international consortium is pooling resources to develop a nasally delivered, cross-strain protective CoV-2 mRNA vaccine. Clinical testing is scheduled for early 2021. Organisations involves include eTheRNA, EpiVax, REPROCELL, Nexelis, and CEV

Gerresheimer part of critical infrastructure, products include vital drug delivery devices

Gerresheimer part of critical infrastructure, products include vital drug delivery devices

In its COVID-19 announcement, Gerresheimer has stated that it is part of the critical infrastructure of the countries in which it operates, producing vital packaging for medicines, drug delivery devices and packaging for food, beverages and hygiene and personal care products.

Catalent Responds to the Global Outbreak of COVID-19

Catalent Responds to the Global Outbreak of COVID-19

Catalent has noted that many governments of the countries where it operates have recognised its work as essential meaning all Catalent operating facilities remain open. The company also said it was working with several customers on COVID-related antivirals, vaccines, and treatments for symptoms and effects of the disease.

With precision metal components being used in inhalers & similar devices, Advanex acknowledges critical role in supply chain

With precision metal components being used in inhalers & similar devices, Advanex acknowledges critical role in supply chain

Advanex acknowledges critical role in supply chains with precision metal components being used in inhalers & similar devices, and commits to maintaining supply during turbulent period.

Elcam Medical facilities Recognised by local authorities as essential, enabling continuation of production

E3D – Elcam Drug Delivery Devices

Elcam Medical facilities Recognised by local authorities as essential, enabling continuation of production

All Elcam facilities have been recognised by the local authorities as an essential facility to enable the continuity of production. (See statement by the Israeli Ministry of Economy and Industry). Currently the company does not foresee any disruption to our operation.

Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19

Lexaria Bioscience

Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19

Lexaria is to investigate how its patented DehydraTECH drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories as soon as possible.

ACG releases letter to customers in response to COVID-19

ACG releases letter to customers in response to COVID-19

ACG has released a letter to its customers in response to the COVID-19 outbreak, and reaffirmed its commitment to providing uninterrupted supply of its products and services, and factories in all locations around the world are working at full capacity. ACG has also ensured the supply of its own raw materials for many months.

PFIZER OUTLINES FIVE-POINT PLAN TO BATTLE COVID-19

PFIZER OUTLINES FIVE-POINT PLAN TO BATTLE COVID-19

Pfizer has called on the biopharmaceutical industry to join it in committing to unprecedented collaboration to combat COVID-19, issuing a five-point plan, which includes applying its drug development expertise, especially to help smaller companies, and offering its manufacturing capabilities.

Prev
1
…
27
28
29
30
31
…
57
Next

See what ondrugdelivery's readers and contributors think

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Top